Raymond Alexanian

Raymond Alexanian

UNVERIFIED PROFILE

Are you Raymond Alexanian?   Register this Author

Register author
Raymond Alexanian

Raymond Alexanian

Publications by authors named "Raymond Alexanian"

Are you Raymond Alexanian?   Register this Author

30Publications

261Reads

13Profile Views

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Am J Hematol 2019 Sep 6. Epub 2019 Sep 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25633DOI Listing
September 2019

High frequencies of response after limited primary therapy for multiple myeloma.

Clin Lymphoma Myeloma Leuk 2013 Apr 20;13(2):119-22. Epub 2012 Dec 20.

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2012.11.008DOI Listing
April 2013

Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.

Am J Clin Oncol 2012 Dec;35(6):562-5

Department of Lymphoma/Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e31822043f6DOI Listing
December 2012

Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

Cancer 2012 Aug 2;118(15):3793-800. Epub 2011 Dec 2.

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26627DOI Listing
August 2012

Curability of multiple myeloma.

Bone Marrow Res 2012 23;2012:916479. Epub 2012 May 23.

University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/916479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366198PMC
August 2012

Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.

Cancer 2011 Oct 22;117(19):4468-74. Epub 2011 Mar 22.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26031DOI Listing
October 2011

Current treatment strategies for multiple myeloma.

Clin Lymphoma Myeloma 2007 Apr;7 Suppl 4:S139-44

Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
April 2007

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.

Am J Hematol 2005 Jul;79(3):194-7

University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.20382
Publisher Site
http://dx.doi.org/10.1002/ajh.20382DOI Listing
July 2005

How we treat Waldenström's macroglobulinemia.

Haematologica 2005 Jan;90(1):117-25

Department of Clinical Therapeutics, University of Athens School of Medicine, Greece.

View Article

Download full-text PDF

Source
January 2005

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.

Cancer 2004 Jun;100(12):2607-12

Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20294DOI Listing
June 2004

High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.

Leuk Lymphoma 2004 Apr;45(4):755-9

Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190310001603957DOI Listing
April 2004

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Semin Hematol 2003 Oct;40(4 Suppl 4):3-7

The University of Texas M.D. Anderson Cancer Center, Box 429, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
October 2003

Thalidomide and dexamethasone for resistant multiple myeloma.

Br J Haematol 2003 Jun;121(5):768-71

University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2141.2003.04345.xDOI Listing
June 2003

2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.

Semin Oncol 2003 Apr;30(2):243-7

Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/sonc.2003.50070DOI Listing
April 2003

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

J Clin Oncol 2003 Jan;21(1):16-9

The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.03.139DOI Listing
January 2003

Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.

Cancer 2002 Mar;94(5):1532-7

Department of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.10366DOI Listing
March 2002